Post-Transplant Glucocorticoid Induced Diabetes Clinical Trial
Official title:
Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia
No consensus guidelines exist for management of post-transplant glucocorticoid induced
hyperglycemia, but most published reviews recommend insulin as first line therapy. A variety
of insulin regimens have been proposed, including mealtime short-acting regular or analog
insulin, once daily neutral protamine hagedorn (NPH) insulin, pre-mixed insulin, or basal
insulin alone such as glargine or detemir. However, no randomized trial has ever examined
different insulin regimens to determine which most effectively controls post-transplant
steroid-induced hyperglycemia. Consequently, the proposed study intends to examine three
commonly used insulin regimens used for managing post-transplant once-daily
glucocorticoid-induced hyperglycemia to determine which is most effective:
- Group 1: Intermediate-acting (NPH) insulin at breakfast
- Group 2: Short-acting insulin (regular or aspart) before meals
- Group 3: Insulin glargine at breakfast
Question/Hypothesis:
Among three commonly used insulin regimens, which is most effective for managing
post-transplant once-daily glucocorticoid-induced hyperglycemia?
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment